Abstract: The invention relates to novel fullerene derivatives, to methods for their preparation and educts or intermediates used therein, to mixtures and formulations containing them, to the use of the fullerene derivatives, mixtures and formulations as organic semiconductors in, or for the preparation of organic electronic (OE) devices, especially organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising, or being prepared from, these fullerene derivatives, mixtures or formulations.

Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.

Abstract: Compounds containing an anionic scaffold structure, dopants and cations, in which a. the anionic scaffold structure features coordination tetrahedra GL4, where G stands for silicon, which may be partly replaced by C, Ge, B, Al or In, and L stands for N and O, with the proviso that N makes up at least 60 atom % of L; b. the cations are alkaline earth metals, with the proviso that strontium and barium together make up less than 75 atom % of the cations; c. dopant present trivalent cerium or a mixture of trivalent cerium and divalent europium; d. charge compensation of the cerium doping is accomplished i) through corresponding replacement of alkaline earth metal cations by alkali metal cations, and/or ii) by a corresponding increase in the nitrogen content, and/or iii) by a corresponding reduction in the cations; and to processes for preparing, and to their use as conversion phosphors.

Abstract: The present invention relates to metal complexes of the formula (1) and to electronic devices, in particular organic electro-luminescent devices, comprising these metal complexes.

Abstract: A method and device for feeding a presettable measurement quantity of a sample liquid from a liquid reservoir via a feed line through a switching valve into a temporary store in order subsequently, after actuation of the switching valve, to feed the sample liquid to an analytical measuring instrument where the sample liquid is conveyed into the temporary store until further conveying of the sample liquid is terminated and the switching valve is actuated by evaluation of a characteristic quantity, wherein a flow rate of the sample liquid is determined at a time at which a first proportion of the sample liquid has already flowed through the switching valve, and the switching valve is actuated as a function of the flow rate determined and a switching delay determined in advance.

Abstract: Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.

Abstract: The invention relates to the process for the preparation of N,N-disubstituted imidazolium salts, N-heterocyclic carbene ligands and ruthenium catalysts containing N-heterocyclic carbene ligands, i.e. compounds of the general formulae (I) and, (II), compounds of the general formulae (III) and (IV) and compounds of the general formulae (V) and (VI), immobilised on inorganic oxide supports. The invention furthermore relates to the use of the immobilised compounds of the general formulae (I-IV) in organic, organometallic or transition metal-catalysed synthesis and to the use of the compounds of the general formulae (V) and (VI) as catalysts in organic and organometallic synthesis, in particular for C—C coupling reactions, such as olefin metathesis.

Abstract: The present invention relates to glycinamide derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.